Results 71 to 80 of about 12,608 (240)

intEgrating Smoking Cessation treatment As part of usual Psychological care for dEpression and anxiety (ESCAPE): A randomised and controlled, multi‐centre, acceptability and feasibility trial with nested qualitative methods

Addiction, Volume 120, Issue 5, Page 922-936, May 2025.
Abstract Background and aim There is evidence that smoking cessation may improve depression and anxiety symptoms. We assessed the feasibility of implementing and trialling a smoking cessation intervention in services providing cognitive behavioural therapy (CBT) for common mental illness. Design, setting and participants This study was a pragmatic, two‐
Gemma M. J. Taylor, Katherine Sawyer, Pamela Jacobsen, Tom P. Freeman, Anna Blackwell, Shadi Daryan, Chris Metcalfe, David Kessler, Marcus R. Munafò, Paul Aveyard   +9 more
wiley   +1 more source

Nicotine receptor partial agonists for smoking cessation

São Paulo Medical Journal
BACKGROUND: Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist)
Kate Cahill, Lindsay F. Stead, Tim Lancaster, Igor Bastos Polonio   +3 more
doaj   +1 more source

What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation

Health Technology Assessment, 2014
Background: Tobacco smoking is one of the leading causes of deaths worldwide. Nearly one-fifth of adults in the UK regularly smoke cigarettes. The ill-health associated with smoking costs the NHS over £3B every year.
Joanna Leaviss, William Sullivan, Shijie Ren, Emma Everson-Hock, Matt Stevenson, John W Stevens, Mark Strong, Anna Cantrell   +7 more
doaj   +1 more source

Varenicline Combined With Oral Nicotine Replacement Therapy and Smartphone-Based Medication Reminders for Smoking Cessation: Feasibility Randomized Controlled Trial

JMIR Formative Research, 2023
BackgroundVarenicline and oral nicotine replacement therapy (NRT) have each been shown to increase the likelihood of smoking cessation, but their combination has not been studied.
Munjireen Sifat, Emily T Hébert, Jasjit S Ahluwalia, Michael S Businelle, Joseph J C Waring, Summer G Frank-Pearce, Chase Bryer, Lizbeth Benson, Stefani Madison, Lourdes G Planas, Irina Baranskaya, Darla E Kendzor   +11 more
doaj   +1 more source

Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives

Advanced Science, Volume 12, Issue 15, April 17, 2025.
Graphic illustration showing the strategic approaches based on the currently investigated evidence of psychedelics that suggests the challenges and how to address the prescription of mental disorders. These applicable avenues may provide substantial insight into distinguishing between brain networks and psychedelics.
Sung‐Hyun Kim, Sumin Yang, Jeehye Jung, Jeonghyeon Choi, Mingon Kang, Jae‐Yeol Joo   +5 more
wiley   +1 more source

Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Varenicline.

Alcoholism: Clinical and Experimental Research, 2020
BACKGROUND The alcohol cue reactivity paradigm is increasingly used to screen medications for the treatment of alcohol use disorder (AUD) and other substance use disorders.
R. Miranda, S. O'Malley, Hayley Treloar Padovano, R. Wu, Daniel E. Falk, Megan L. Ryan, J. Fertig, Thomas Chun, Srinivas B. Muvvala, R. Litten   +9 more
semanticscholar   +1 more source

Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review

BMC Public Health
Background Adhering to varenicline has been shown to significantly improve the chances of successfully quitting smoking, with studies indicating a twofold increase in 6-month quit rates.
Nadia Minian, Melissa Wong, Sowsan Hafuth, Terri Rodak, Alma Rahimi, Dea Gjomema, Jonathan Rose, Laurie Zawertailo, Matt Ratto, Peter Selby   +9 more
doaj   +1 more source

Varenicline Targets the Reinforcing-Enhancing Effect of Nicotine on Its Associated Salient Cue During Nicotine Self-administration in the Rat

Frontiers in Behavioral Neuroscience, 2019
Nicotine is acknowledged as the key addictive compound of tobacco. Varenicline (Champix® or Chantix®), mainly acting as a partial agonist at the α4β2 nicotinic receptor, is an approved smoking cessation pharmacotherapy, although with efficacy limited to ...
Vernon Garcia-Rivas, Vernon Garcia-Rivas, Jean-François Fiancette, Jean-François Fiancette, Nazzareno Cannella, Nazzareno Cannella, Maria Carbo-Gas, Maria Carbo-Gas, Prisca Renault, Prisca Renault, Jessica Tostain, Jessica Tostain, Véronique Deroche-Gamonet, Véronique Deroche-Gamonet   +13 more
doaj   +1 more source

Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo‐Controlled Trial

Clinical pharmacology and therapy, 2020
It is unclear if genetic variants affect smoking cessation treatment response. This study tested whether variants in the cholinergic receptor nicotinic alpha 5 subunit (CHRNA5) predict response to smoking cessation medication by directly comparing the ...
Li-Shiun Chen, T. Baker, J. Miller, M. Bray, Nina Smock, Jingling Chen, Faith Stoneking, R. Culverhouse, N. Saccone, Christopher I. Amos, R. Carney, D. Jorenby, L. Bierut   +12 more
semanticscholar   +1 more source

Safety of varenicline as an aid to smoking cessation in professional drivers and its impact on driving behaviors: An observational cohort study of taxi drivers in Beijing

Tobacco Induced Diseases, 2020
Introduction Varenicline is an effective smoking cessation medicine. However, the possible adverse neuropsychiatric events reported by Food and Drug Administration for varenicline may cause safety problems for professional drivers.
Shuilian Chu, Lirong Liang, Hang Jing, Di Zhang, Zhaohui Tong   +4 more
doaj   +1 more source